HUTCHMED (China) (HUTCHMED (China)) Interest Expense : $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. HUTCHMED (China)'s interest expense for the six months ended in Dec. 2023 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. HUTCHMED (China)'s Operating Income for the six months ended in Dec. 2023 was $ -93.3 Mil. HUTCHMED (China)'s Interest Expense for the six months ended in Dec. 2023 was $ 0.0 Mil. GuruFocus does not calculate HUTCHMED (China)'s interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HUTCHMED (China) Interest Expense Historical Data

The historical data trend for HUTCHMED (China)'s Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) Interest Expense Chart

HUTCHMED (China) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.03

-0.79

-0.59

-0.65

-0.76

HUTCHMED (China) Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

HUTCHMED (China) Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

HUTCHMED (China) (NAS:HCM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

HUTCHMED (China)'s Interest Expense for the six months ended in Dec. 2023 was $0.0 Mil. Its Operating Income for the six months ended in Dec. 2023 was $-93.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was $51.0 Mil.

HUTCHMED (China)'s Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate HUTCHMED (China)'s interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. HUTCHMED (China) Ltd has enough cash to cover all of its debt. Its financial situation is stable.

HUTCHMED (China) (HUTCHMED (China)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

00013:Hong Kong HCM.GB:UK HCM:UK H7T2:Germany

Address

2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG

Website

https://www.hutch-med.com

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.